Question 1

What are the most cited papers from Novasep (Belgium)?

Accepted Answer

The most cited paper from Novasep (Belgium) is "Recombinant gp350 Vaccine for Infectious Mononucleosis: A Phase 2, Randomized, Double‐Blind, Placebo‐Controlled Trial to Evaluate the Safety, Immunogenicity, and Efficacy of an Epstein‐Barr Virus Vaccine in Healthy Young Adults" (Etienne Marc Sokal, Karel Hoppenbrouwers, Corinne Vandermeulen et al., 2007), with 431 citations. Next come "Phase I/II studies to evaluate safety and immunogenicity of a recombinant gp350 Epstein–Barr virus vaccine in healthy adults" (181) and "Large-scale monoclonal antibody purification by continuous chromatography, from process design to scale-up" (75).

Question 2

Which research topics does Novasep (Belgium) publish most on?

Accepted Answer

By volume: Virus-based gene therapy research, Viral Infectious Diseases and Gene Expression in Insects, Biofuel production and bioconversion and Protein purification and stability.

Question 3

Which fields of science does Novasep (Belgium) work in?

Accepted Answer

In all years, 43% of research at Novasep (Belgium) is in Life Sciences, 36% in Health Sciences. Its largest fields are Medicine (36%), Biochemistry, Genetics and Molecular Biology (32%), Social Sciences (11%). It does 1.4× the world's share of Life Sciences.